<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01701986</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0506</org_study_id>
    <secondary_id>NCI-2012-02055</secondary_id>
    <secondary_id>2012-0506</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT01701986</nct_id>
  </id_info>
  <brief_title>Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma</brief_title>
  <official_title>Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of gemcitabine hydrochloride,
      clofarabine, and busulfan before donor stem cell transplant and to see how well it works in
      treating patients with B-cell or T-cell non-Hodgkin lymphoma or Hodgkin lymphoma that does
      not respond to treatment. Giving chemotherapy before a donor bone marrow or peripheral blood
      stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's
      immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor
      are infused into the patient they may help the patient's bone marrow make stem cells, red
      blood cells, white blood cells, and platelets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To define the maximum tolerated dose (MTD) of infusional gemcitabine (gemcitabine
      hydrochloride) combined with fixed doses of clofarabine and busulfan in patients with
      lymphoma receiving an allogeneic stem-cell transplant (alloSCT).

      II. To estimate the day +100 success rate, defined as percentage of patients who are alive,
      engrafted and without grade 3-4 graft-versus (vs.)-host-disease (GVHD).

      SECONDARY OBJECTIVES:

      I. To estimate the day +100 success rate (defined as percentage of patients who are alive,
      engrafted and without grade 3-4 graft-vs.-host-disease [GVHD]).

      II. To estimate the rate of event-free (EFS). III. To estimate the rate of overall survival
      (OS). IV. To estimate the response rate (RR) (defined as # of responses / # of patients with
      measurable tumors).

      V. To estimate the complete response (CR) rate (defined as # of complete responses / # of
      patients with measurable tumors).

      VI. To estimate the incidence of grade 2-4 and grade 3-4 acute GVHD. VII. To estimate the
      incidence of limited and extensive chronic GVHD.

      OUTLINE: This is a phase I, dose-escalation study of gemcitabine hydrochloride followed by a
      phase II study.

      PREPARATIVE REGIMEN: Patients receive gemcitabine hydrochloride intravenously (IV) over
      40-180 minutes on days -6 and -4, clofarabine IV over 1 hour on days -6 to -3, and busulfan
      IV over 3 hours on days -6 to -3. Patients with matched unrelated donors also receive
      antithymocyte globulin IV on days -3 to -1 and patients with cluster of differentiation
      (CD)20-positive disease also receive rituximab IV on days -14, -7, 1, and 8.

      TRANSPLANT: Patients undergo allogeneic bone marrow (BMT) or peripheral blood stem cell
      transplant (PBSCT) on day 0.

      GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously over 24 hours or orally (PO).
      Beginning on day 0, patients receive mycophenolate mofetil IV over 2 hours or PO thrice daily
      (TID).

      After completion of study treatment, patients are followed up at 3, 6, and 12 months, and
      then every 6 months for 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2012</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal dose of gemcitabine hydrochloride determined by dose limiting toxicity (Phase I)</measure>
    <time_frame>Within 30 days of transplant</time_frame>
    <description>Defined as grade 3-4 mucositis lasting for more than 3 days at peak severity or grade 3-4 skin toxicity lasting for more than 3 days at peak severity. The Bayesian Time to Event Continual Reassessment Method will be applied to determine the optimal gemcitabine dose in phase I.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Success rate (Phase II)</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
    <description>Defined as percentage of patients who are alive, engrafted and without grade 3-4 graft versus host disease (GVHD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of event-free survival (Phase II)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (Phase II)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate (Phase II)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response rate (Phase II)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of grade 2-4 and grade 3-4 acute GVHD (Phase II)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of limited and extensive chronic GVHD (Phase II)</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hematopoietic Cell Transplantation Recipient</condition>
  <condition>Refractory B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Hodgkin Lymphoma</condition>
  <condition>Refractory T-Cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PREPARATIVE REGIMEN: Patients receive gemcitabine hydrochloride IV over 40-180 minutes on days -6 and -4, clofarabine IV over 1 hour on days -6 to -3, and busulfan IV over 3 hours on days -6 to -3. Patients with matched unrelated donors also receive antithymocyte globulin IV on days -3 to -1 and patients with CD20-positive disease also receive rituximab IV on days -14, -7, 1, and 8.
TRANSPLANT: Patients undergo allogeneic BMT or PBSCT on day 0.
GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously over 24 hours or PO beginning on day -2 for up to 6 months and mycophenolate mofetil IV over 2 hours or PO TID beginning day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Undergo allogeneic BMT</description>
    <arm_group_label>Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic BMT or PBSCT</description>
    <arm_group_label>Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>ATS</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)</arm_group_label>
    <other_name>Clofarex</other_name>
    <other_name>Clolar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
    <other_name>LY188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV then PO</description>
    <arm_group_label>Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic PBSCT</description>
    <arm_group_label>Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV then PO</description>
    <arm_group_label>Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with refractory B-cell or T-cell non-Hodgkin's lymphoma or Hodgkin's lymphoma
             who are eligible for allogeneic transplantation

          -  An 8/8 human leukocyte antigen (HLA) matched (high resolution typing at A, B, C, DRB1)
             sibling or unrelated donor

          -  Left ventricular ejection fraction (EF) &gt;= 45%

          -  Forced expiratory volume in one second (FEV1) &gt;= 50%

          -  Forced vital capacity (FVC) &gt;= 50%

          -  Diffusing capacity of the lung for carbon monoxide (DLCO) &gt;= 50%

          -  Estimated serum creatinine clearance &gt;= 50 ml/min (using the Cockcroft-Gault formula)

          -  Serum creatinine =&lt; 1.6 mg/dL

          -  Serum bilirubin =&lt; 2 x upper limit of normal

          -  Serum glutamate pyruvate transaminase (SGPT) =&lt; 2 x upper limit of normal

          -  Voluntary signed Institutional Review Board (IRB)-approved informed consent before
             performance of any study-related procedure not part of normal medical care, with the
             understanding that consent may be withdrawn by the subject at any time without
             prejudice to future medical care

          -  Men and women of reproductive potential must agree to follow accepted birth control
             methods for the duration of the study; female subject is either post-menopausal or
             surgically sterilized or willing to use an acceptable method of birth control (i.e., a
             hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with
             spermicide, or abstinence) for the duration of the study; male subject agrees to use
             an acceptable method for contraception for the duration of the study

        Exclusion Criteria:

          -  Patient with active central nervous system (CNS) disease

          -  Pregnancy (positive beta human chorionic gonadotropin [HCG] test in a woman with child
             bearing potential defined as not post-menopausal for 12 months or no previous surgical
             sterilization) or currently breast-feeding; pregnancy testing is not required for
             post-menopausal or surgically sterilized women

          -  Active hepatitis B, either active carrier (hepatitis B virus surface antigen [HBsAg]
             +) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] &gt;= 10,000
             copies/mL, or &gt;= 2,000 IU/mL)

          -  Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic
             hepatitis C or positive hepatitis C serology

          -  Human immunodeficiency virus (HIV) infection

          -  Active uncontrolled bacterial, viral or fungal infections

          -  Exposure to other investigational drugs within 2 weeks before enrollment

          -  Grade &gt;= 3 non-hematologic toxicity from previous therapy that has not resolved to =&lt;
             grade 1

          -  Radiation therapy to head and neck (excluding eyes), and internal organs of chest,
             abdomen or pelvis in the month prior to enrollment

          -  Prior whole brain irradiation

          -  Prior autologous stem-cell transplant (SCT) in the prior 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yago L Nieto, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yago Nieto, MD,PHD</last_name>
    <phone>713-792-2466</phone>
    <email>ynieto@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yago L. Nieto, MD,PHD</last_name>
      <phone>713-792-8750</phone>
    </contact>
    <investigator>
      <last_name>Yago L. Nieto, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 3, 2012</study_first_submitted>
  <study_first_submitted_qc>October 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2012</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

